Crossmark

Irisin mitigates osteoporotic-associated bone loss and gut dysbiosis in ovariectomized mice by modulating microbiota, metabolites, and intestinal barrier integrity

Crossref DOI link: https://doi.org/10.1186/s12891-025-08622-y

Published Online: 2025-04-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yiran

Deng, Huimin

Zhang, Zhihui

Wu, Hongbo

Wang, Xiaofeng

Zhang, Zhiwen
License Information

Text and Data Mining valid from 2025-04-16

Version of Record valid from 2025-04-16
More Information

Article History

Received: 12 February 2025

Accepted: 4 April 2025

First Online: 16 April 2025

Declarations

:

: All animal experimental procedures were approved by Laboratory Animal Ethics Committee of Lai’an Technology (Guangzhou) Co., LTD (Approval number: G2024094), and were carried out in compliance with the ARRIVE guidelines () regarding the care and use of laboratory animals. Clinical trial number: not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below